Lacosamidă Teva

Lacosamide, the active ingredient in Lacosamidă Teva, is an anticonvulsant presented as an oral tablet for oral use. It is indicated for the treatment of partial‑onset seizures and is used as adjunctive therapy in patients with epilepsy. GNH USA supplies Lacosamidă Teva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lacosamide is an anticonvulsant that targets seizure activity in the central nervous system. - Partial‑onset seizures: reduces the frequency of focal seizures when added to existing therapy. - Adjunctive therapy for epilepsy: improves overall seizure control as part of combination treatment. - Focal seizures: helps achieve better seizure management in patients with focal onset epilepsy.

Lacosamide may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Dizziness: sensation of light‑headedness or unsteadiness. - Nausea: mild to moderate stomach upset. - Fatigue: feeling unusually tired or weak. - Headache: mild to moderate cranial pain. - Diplopia: transient double vision. - Tremor: fine shaking of the hands or limbs.

Serious or Rare Side Effects: - Cardiac arrhythmia: irregular heart rhythm, including PR‑interval prolongation. - Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Suicidal ideation: thoughts of self‑harm or suicide. - Hepatic dysfunction: elevated liver enzymes or hepatitis. - Acute pancreatitis: inflammation of the pancreas. - Anaphylaxis: severe allergic reaction with breathing difficulty.

Before initiating therapy, clinicians should evaluate patient history and monitor for specific risks. - Renal impairment: adjust monitoring as drug is renally excreted. - Hepatic dysfunction: assess liver function tests regularly. - Cardiac conduction disorders: obtain baseline ECG and monitor PR interval. - Pregnancy and lactation: use only if potential benefit outweighs risk, as safety data are limited. - Store at ambient temperature: keep below 25°C in the original container, protect from moisture and direct sunlight.

Lacosamide can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., carbamazepine, phenytoin): may reduce lacosamide plasma levels. - Concomitant use with other sodium‑channel blockers (e.g., lamotrigine) at high doses: increased risk of cardiac conduction effects.

Moderate Interactions (Monitor Closely): - CYP2C19 inhibitors (e.g., fluoxetine, omeprazole): may increase lacosamide exposure. - Anticoagulants (e.g., warfarin): monitor INR for potential changes. - Alcohol: may enhance central nervous system depression. - Other antiepileptic drugs: assess for additive sedation or efficacy changes.